Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of June 30th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups. </li>
<li>We estimate that the outflows were USD 20 million and highlight flows for ICBC.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of June 30th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups. 
We estimate that the outflows were USD 20 million and highlight flows for ICBC.


<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of June 16th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We estimate the inflows to be USD 1.5bn and highlight flows for CCB.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of June 16th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We estimate the inflows to be USD 1.5bn and highlight flows for CCB.


HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>TAVR was once envisioned with infinite optimism as a "hundred billion yuan market", attracting massive amounts of capital/companies to enter. However, the commercialization status of TAVR companies is much bleak.</li>
<li>High cost of TAVR surgery without medical insurance reimbursement and limited number of qualified hospitals to carry out such complicated surgery are the major reasons for the unsatisfactory sales growth. </li>
<li>Venus Medtech's market share would continue to be challenged. MicroPort CardioFlow's low gross margin and slow product iteration are the problems. Peijia could be “dark horse” if positive momentum continues. </li>
</ul>


TAVR was once envisioned with infinite optimism as a "hundred billion yuan market", attracting massive amounts of capital/companies to enter. However, the commercialization status of TAVR companies is much bleak.
High cost of TAVR surgery without medical insurance reimbursement and limited number of qualified hospitals to carry out such complicated surgery are the major reasons for the unsatisfactory sales growth. 
Venus Medtech's market share would continue to be challenged. MicroPort CardioFlow's low gross margin and slow product iteration are the problems. Peijia could be “dark horse” if positive momentum continues. 


CardioFlow (2160.HK) Vs Venus MedTech (2500.HK) Vs Peijia Medical (9996.HK) - Dark Horse Is Emerging

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Venus Medtech (Hangzhou) / Equity Bottom-Up

<ul><li>Venus Medtech reported FY22 revenue of RMB406.5mn, down by 2.3% YoY due to the decreased volume of TAVR surgeries amid COVID-19 pandemic.</li><li>Gross profit margin declined from 78.0% in 2021 to 77.2% due to the slight decrease in ASP.</li><li>Given the significant losses incurred from the business termination of Keystone and the increase in R&amp;D costs and administrative expenses after the acquisition of Cardiovalve, the attributable net loss widened from RMB373.6mn in 2021 to RMB1,057.7mn in 2022, missing our forecast of RMB409.6mn net loss in 2022.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Venus Medtech reported FY22 revenue of RMB406.5mn, down by 2.3% YoY due to the decreased volume of TAVR surgeries amid COVID-19 pandemic.Gross profit margin declined from 78.0% in 2021 to 77.2% due to the slight decrease in ASP.Given the significant losses incurred from the business termination of Keystone and the increase in R&amp;D costs and administrative expenses after the acquisition of Cardiovalve, the attributable net loss widened from RMB373.6mn in 2021 to RMB1,057.7mn in 2022, missing our forecast of RMB409.6mn net loss in 2022.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Venus Medtech (2500 HK) – Expect sales turnaround in 2023

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 1st.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Great Wall Motor, China Construction Bank, Hong Kong Exchanges And Clearing.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 1st.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Great Wall Motor, China Construction Bank, Hong Kong Exchanges And Clearing.


Hong Kong Connect Flows (Mar 1st): Tencent, Great Wall Motor, CCB, HKEx

China

Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Venus Medtech (Hangzhou) (2500 HK)

Hong Kong Connect Flows (Jun 30th): ICBC

We analyzed southbound Hong Kong connect flows in the past week. We estimate the outflows to be USD 20 million and highlight flows for ICBC.

Ke Yan, CFA, FRM

Hong Kong Connect Flows (Jun 16th): CCB

We analyzed the Hong Kong Connect Scheme for last week. We estimate the inflows to be USD 1.5bn and highlight flows for China Construction Bank.

Ke Yan, CFA, FRM

CardioFlow (2160.HK) Vs Venus MedTech (2500.HK) Vs Peijia Medical (9996.HK) - Dark Horse Is Emerging

After four years of anticipation, the golden age of TAVR still has not arrived. Although there are common industry pain points, CardioFlow/Venus...

Xinyao (Criss) Wang

Venus Medtech (2500 HK) – Expect sales turnaround in 2023

Venus Medtech reported FY22 revenue of RMB406.5mn, down by 2.3% YoY due to the decreased volume of TAVR surgeries amid COVID-19 pandemic

CMB International

Hong Kong Connect Flows (Mar 1st): Tencent, Great Wall Motor, CCB, HKEx

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Tencent, Great Wall Motor, CCB, Hong Kong Exchanges And...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)